| abstract |
The present invention relates to chemically modified RNAi constructs for reducing the expression of target genes. In particular, the present invention relates to specific patterns of modified nucleotides incorporated into RNAi constructs to improve in vivo stability and efficacy. In addition, pharmaceutical compositions comprising the chemically modified RNAi construct and, for example, to treat or ameliorate various disease states, inhibit target gene expression in vivo by administering the chemically modified RNAi construct. A method is described. |